Sidley advised I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, in its strategic collaboration agreement with Jumpcan Pharmaceutical Group for the development, manufacturing, and commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa (TJ101) in mainland China.
I-Mab will be the marketing authorization holder (MAH) of the product and supply the product at agreed cost to Jumpcan. Jumpcan will be responsible for commercializing the product and developing new indications in collaboration with I-Mab in mainland China. According to the terms of the collaboration agreement, Jumpcan will pay I-Mab a total of up to RMB 2.016 billion (approximately $315 million), including the upfront payment of RMB 224 million (approximately $35 million), and the parties will share profits generated from commercialization of the product in mainland China.
The Sidley team was led by partner Ruchun Ji, with the support of associate Longbo Wang, senior counsel Chen Yang, and associate Rui Liu.
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business lifecycles, ranging from formation, corporate governance, and compliance operations for start-ups, to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, equity financings, and bond/note issuances, as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.